Insights into cytokine-receptor interactions from cytokine engineering

Annual Review of Immunology

Volumn 33, Issue , 2015, Pages 139-167

  Spangler, Jamie B ^a   Moraga, Ignacio ^a   Mendoza, Juan L ^a   Garcia, K Christopher ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immune signaling; Immunotherapeutics; Interferon; Interleukin; Ligand receptor interaction; Protein design

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; CYTOKINE RECEPTOR AGONIST; CYTOKINE RECEPTOR ANTAGONIST; INTERFERON; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; PROTEIN BINDING;

ADAPTIVE IMMUNITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CELL FUNCTION; CELL MIGRATION; CRYSTAL STRUCTURE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME MECHANISM; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; INTRACELLULAR SIGNALING; MOLECULAR BIOLOGY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TARGET CELL; TAXONOMY; WORKFLOW; ANIMAL; CHEMISTRY; EXTRACELLULAR SPACE; GENETIC ENGINEERING; GENETICS; INTRACELLULAR SPACE; METABOLISM; PROTEIN TRANSPORT;

ANIMALS; CYTOKINES; EXTRACELLULAR SPACE; GENETIC ENGINEERING; HUMANS; INTRACELLULAR SPACE; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION;

EID: 84925518929     PISSN: 07320582     EISSN: 15453278     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-032713-120211     Document Type: Review

References (198)

1. Watowich SS, Hilton DJ, Lodish HF. 1994. Activation and inhibition of erythropoietin receptor function: role of receptor dimerization. Mol. Cell. Biol. 14:3535-49
2. Wang X, Lupardus P, Laporte SL, Garcia KC. 2009. Structural biology of shared cytokine receptors. Annu. Rev. Immunol. 27:29-60
3. Stroud RM,Wells JA. 2004. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci. STKE 2004:re7
4. Kossiakoff AA, De Vos AM. 1998. Structural basis for cytokine hormone-receptor recognition and receptor activation. Adv. Protein Chem. 52:67-108
5. Schreiber G,Walter MR. 2010. Cytokine-receptor interactions as drug targets. Curr. Opin. Chem. Biol. 14:511-19
6. Broughton SE, Hercus TR, LopezAF, ParkerMW.2012. Cytokine receptor activation at the cell surface. Curr. Opin. Struct. Biol. 22:350-59
7. BoulangerMJ, Garcia KC. 2004. Shared cytokine signaling receptors: structural insights from the gp130 system. Adv. Protein Chem. 68:107-46
8. Bazan JF. 1990. Haemopoietic receptors and helical cytokines. Immunol. Today 11:350-54
9. Bazan JF. 1989. A novel family of growth factor receptors: a common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chain. Biochem. Biophys. Res. Commun. 164:788-95
10. Rochman Y, Spolski R, Leonard WJ. 2009. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9:480-90
11. O'Shea JJ, Plenge R. 2012. JAK and STAT signaling molecules in immunoregulation and immunemediated disease. Immunity 36:542-50
12. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Silvennoinen O. 1995. Signaling through the hematopoietic cytokine receptors. Annu. Rev. Immunol. 13:369-98
13. Levy DE, Darnell JE Jr. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3:651-62
14. Murray PJ. 2007. The JAK-STAT signaling pathway: input and output integration. J. Immunol. 178:2623-29
15. Platanias LC. 2005. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5:375-86
16. van Boxel-Dezaire AH, Rani MR, Stark GR. 2006. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25:361-72
17. Schindler C, Levy DE, Decker T. 2007. JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282:20059-63
18. Malek TR. 2008. The biology of interleukin-2. Annu. Rev. Immunol. 26:453-79
19. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374:1-20
20. Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, et al. 2012. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol. Rev. 250:277-302
21. Kallen KJ, Grotzinger J, Rose-John S. 2000. New perspectives on the design of cytokines and growth factors. Trends Biotechnol. 18:455-61
22. Wells JA, de Vos AM. 1996. Hematopoietic receptor complexes. Annu. Rev. Biochem. 65:609-34
23. Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, et al. 1998. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395:511-16
24. Watowich SS, Wu H, Socolovsky M, Klingmuller U, Constantinescu SN, Lodish HF. 1996. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu. Rev. Cell Dev. Biol. 12:91-128
25. Cunningham BC, Ultsch M, De Vos AM, MulkerrinMG, Clauser KR, Wells JA. 1991. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254:821-25
26. Constantinescu SN, Keren T, Socolovsky M, NamH,Henis YI, Lodish HF. 2001. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. PNAS 98:4379-84
27. Livnah O, SturaEA, Middleton SA, Johnson DL, Jolliffe LK,Wilson IA. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283:987-90
28. Brooks AJ, DaiW, O'MaraML, AbankwaD, Chhabra Y, et al. 2014. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 344:1249783
29. Lemmon MA, Schlessinger J. 2010. Cell signaling by receptor tyrosine kinases. Cell 141:1117-34
30. Ozaki K, Leonard WJ. 2002. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 277:29355-58
31. Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, et al. 2013. Signalling by the βc family of cytokines. Cytokine Growth Factor Rev. 24:189-201
32. de Vos AM, Ultsch M, Kossiakoff AA. 1992. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-12
33. Pestka S, Krause CD, Walter MR. 2004. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 202:8-32
34. Rickert M, Boulanger MJ, Goriatcheva N, Garcia KC. 2004. Compensatory energetic mechanisms mediating the assembly of signaling complexes between interleukin-2 and its α, β, and γc receptors. J. Mol. Biol. 339:1115-28
35. Letzelter F, Wang Y, Sebald W. 1998. The interleukin-4 site-2 epitope determining binding of the common receptor gamma chain. Eur. J. Biochem. 257:11-20
36. LaPorte SL, Juo ZS, Vaclavikova J, Colf LA, Qi X, et al. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell 132:259-72
37. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, et al. 2012. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat. Immunol. 13:1187-95
38. Roisman LC, Jaitin DA, Baker DP, Schreiber G. 2005. Mutational analysis of the IFNAR1 binding site on IFNα2 reveals the architecture of a weak ligand-receptor binding-site. J. Mol. Biol. 353:271-81
39. Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G. 2008. The stability of the ternary interferonreceptor complex rather than the affinity to the individual subunits dictates differential biological activities. J. Biol. Chem. 283:32925-36
40. Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, et al. 2011. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146:621-32
41. Kruse N, Tony HP, Sebald W. 1992. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. EMBO J. 11:3237-44
42. Kraich M, Klein M, Patino E, Harrer H, Nickel J, et al. 2006. A modular interface of IL-4 allows for scalable affinity without affecting specificity for the IL-4 receptor. BMC Biol. 4:13
43. Fuh G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. 1992. Rational design of potent antagonists to the human growth hormone receptor. Science 256:1677-80
44. Lowman HB, Wells JA. 1993. Affinity maturation of human growth hormone by monovalent phage display. J. Mol. Biol. 234:564-78
45. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. 2003. Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex. Science 300:2101-4
46. Chow D, He X, Snow AL, Rose-John S, Garcia KC. 2001. Structure of an extracellular gp130 cytokine receptor signaling complex. Science 291:2150-55
47. Bravo J, Heath JK. 2000. Receptor recognition by gp130 cytokines. EMBO J. 19:2399-411
48. Matadeen R, Hon WC, Heath JK, Jones EY, Fuller S. 2007. The dynamics of signal triggering in a gp130-receptor complex. Structure 15:441-48
49. Carr PD, Gustin SE, Church AP, Murphy JM, Ford SC, et al. 2001. Structure of the complete extracellular domain of the common beta subunit of the human GM-CSF, IL-3, and IL-5 receptors reveals a novel dimer configuration. Cell 104:291-300
50. Tamada T, Honjo E, Maeda Y, Okamoto T, Ishibashi M, et al. 2006. Homodimeric cross-over structure of the human granulocyte colony-stimulating factor (GCSF) receptor signaling complex. PNAS 103:3135-40
51. Boulanger MJ, Chow D, Brevnova E, Martick M, Sandford G, et al. 2004. Molecular mechanisms for viralmimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J. Mol. Biol. 335:641-54
52. Beyer BM, Ingram R, Ramanathan L, Reichert P, Le HV, et al. 2008. Crystal structures of the proinflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. J. Mol. Biol. 382:942-55
53. Lupardus PJ,Garcia KC. 2008. The structure of interleukin-23 reveals themolecular basis of p40 subunit sharing with interleukin-12. J. Mol. Biol. 382:931-41
54. Fairlie WD, Uboldi AD, McCoubrie JE,Wang CC, Lee EF, et al. 2003. Affinity maturation of leukemia inhibitory factor and conversion to potent antagonists of signaling. J. Biol. Chem. 279:2125-34
55. Hansen G, Hercus TR,McClure BJ, Stomski FC, Dottore M, et al. 2008. The structure of theGM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134:496-507
56. Patino E, Kotzsch A, Saremba S, Nickel J, SchmitzW, et al. 2011. Structure analysis of the IL-5 ligandreceptor complex reveals a wrench-like architecture for IL-5Rα. Structure 19:1864-75
57. Lupardus PJ, BirnbaumME, Garcia KC. 2010. Molecular basis for shared cytokine recognition revealed in the structure of an unusually high affinity complex between IL-13 and IL-13Rα2. Structure 18:332-42
58. Chirifu M, Hayashi C, Nakamura T, Toma S, Shuto T, et al. 2007. Crystal structure of the IL-15-IL-15Rαcomplex, a cytokine-receptor unit presented in trans. Nat. Immunol. 8:1001-7
59. Jones BC, Logsdon NJ,Walter MR. 2008. Structure of IL-22 bound to its high-affinity IL-22R1 chain. Structure 16:1333-44
60. Josephson K, Logsdon NJ, Walter MR. 2001. Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15:35-46
61. Walter MR,Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, et al. 1995. Crystal structure of a complex between interferon-γand its soluble high-affinity receptor. Nature 376:230-35
62. Nicola NA, Hilton DJ. 1998. General classes and functions of four-helix bundle cytokines. Adv. Protein Chem. 52:1-65
63. DominguesH, Cregut D, Sebald W, Oschkinat H, Serrano L. 1999. Rational design of aGCN4-derived mimetic of interleukin-4. Nat. Struct. Biol. 6:652-56
64. Laporte SL, Forsyth CM, Cunningham BC, Miercke LJ, Akhavan D, Stroud RM. 2005. De novo design of an IL-4 antagonist and its structure at 1.9A . PNAS 102:1889-94
65. Sprang SR, Bazan JF. 1993. Cytokine structural taxonomy and mechanisms of receptor engagement. Curr. Opin. Struct. Biol. 3:815-27
66. Bazan JF. 1993. Emerging families of cytokines and receptors. Curr. Biol. 3:603-6
67. Bazan JF. 1990. Structural design and molecular evolution of a cytokine receptor superfamily. PNAS 87:6934-38
68. Cunningham BC, Henner DJ, Wells JA. 1990. Engineering human prolactin to bind to the human growth hormone receptor. Science 247:1461-65
69. Cunningham BC, Bass S, Fuh G, Wells JA. 1990. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 250:1709-12
70. Cunningham BC, Wells JA. 1989. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244:1081-85
71. Cunningham BC, Jhurani P, Ng P, Wells JA. 1989. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science 243:1330-36
72. Cunningham BC, Wells JA. 1991. Rational design of receptor-specific variants of human growth hormone. PNAS 88:3407-11
73. Frisch C, Schreiber G, Johnson CM, Fersht AR. 1997. Thermodynamics of the interaction of barnase and barstar: changes in free energy versus changes in enthalpy on mutation. J. Mol. Biol. 267:696-706
74. Pal G, UltschMH, Clark KP, Currell B, Kossiakoff AA, Sidhu SS. 2005. Intramolecular cooperativity in a protein binding site assessed by combinatorial shotgun scanning mutagenesis. J. Mol. Biol. 347:489-94
75. Cassell DJ, Choudhri S, Humphrey R, Martell RE, Reynolds T, Shanafelt AB. 2002. Therapeutic enhancement of IL-2 through molecular design. Curr. Pharm. Des. 8:2171-83
76. Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, et al. 2000. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18:1197-202
77. Kang L, Bondensgaard K, Li T, Hartmann R, Hjorth SA. 2010. Rational design of interleukin-21 antagonist through selective elimination of the γC binding epitope. J. Biol. Chem. 285:12223-31
78. Kallen KJ, Grotzinger J, Lelievre E, Vollmer P, Aasland D, et al. 1999. Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptorbinding site from ciliary neurotrophic factor to interleukin-6. J. Biol. Chem. 274:11859-67
79. Brideau-Andersen AD, Huang X, Sun SC, Chen TT, Stark D, et al. 2007. Directed evolution of geneshuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases. PNAS 104:8269-74
80. Rao BM, Girvin AT, Ciardelli T, Lauffenburger DA, Wittrup KD. 2003. Interleukin-2 mutants with enhanced α-receptor subunit binding affinity. Protein Eng. 16:1081-87
81. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, et al. 2012. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine.' Nature 484:529-33
82. Clackson T, Wells JA. 1995. A hot spot of binding energy in a hormone-receptor interface. Science 267:383-86
83. Zhang JL, Simeonowa I,Wang Y, Sebald W. 2002. The high-affinity interaction of human IL-4 and the receptor αchain is constituted by two independent binding clusters. J. Mol. Biol. 315:399-407
84. Junttila IS, Creusot RJ, Moraga I, Bates DL, Wong MT, et al. 2012. Redirecting cell-type specific cytokine responses with engineered interleukin-4 superkines. Nat. Chem. Biol. 8:990-98
85. Kalie E, Jaitin DA, Abramovich R, Schreiber G. 2007. An interferon α2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities. J. Biol. Chem. 282:11602-11
86. Zurawski SM, Imler JL, Zurawski G. 1990. Partial agonist/antagonist mouse interleukin-2 proteins indicate that a third component of the receptor complex functions in signal transduction. EMBO J. 9:3899-905
87. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. 1993. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J. 12:2663-70
88. Levin D, Schneider WM, Hoffmann HH, Yarden G, Busetto AG, et al. 2014. Multifaceted activities of type I interferon are revealed by a receptor antagonist. Sci. Signal. 7:ra50
89. Boulanger MJ, Bankovich AJ, Kortemme T, Baker D, Garcia KC. 2003. Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol. Cell 12:577-89
90. Chao G, LauWL, Hackel BJ, Sazinsky SL, Lippow SM,Wittrup KD. 2006. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1:755-68
91. Boder ET, Wittrup KD. 1997. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15:553-57
92. Levin AM, Weiss GA. 2006. Optimizing the affinity and specificity of proteins with molecular display. Mol. Biosyst. 2:49-57
93. Piehler J, Thomas C, Garcia KC, Schreiber G. 2012. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation. Immunol. Rev. 250:317-34
94. Gonzalez-Navajas JM, Lee J,David M, Raz E. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12:125-35
95. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, et al. 2007. Interferons at age 50: past, current and future impact on biomedicine. Nat. Rev. Drug Discov. 6:975-90
96. Wang BX, Rahbar R, Fish EN. 2011. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 31:545-52
97. Moraga I, Harari D, Schreiber G, Uze G, Pellegrini S. 2009. Receptor density is key to the α2/β interferon differential activities. Mol. Cell. Biol. 29:4778-87
98. Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, et al. 2011. Binding and activity of all human αinterferon subtypes. Cytokine 56:282-89
99. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. 2007. Differential receptor subunit affinities of type I interferons govern differential signal activation. J. Mol. Biol. 366:525-39
100. Subramaniam PS, Khan SA, Pontzer CH, Johnson HM. 1995. Differential recognition of the type I interferon receptor by interferons τ and αis responsible for their disparate cytotoxicities. PNAS 92:12270-74
101. Jaitin DA, Roisman LC, Jaks E, Gavutis M, Piehler J, et al. 2006. Inquiring into the differential action of interferons (IFNs): an IFN-α2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-β. Mol. Cell. Biol. 26:1888-97
102. Schiller JH, Willson JK, Bittner G, Wolberg WH, Hawkins MJ, Borden EC. 1986. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J. Interferon Res. 6:615-25
103. de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, et al. 2013. Structural basis of a unique interferon-βsignaling axis mediated via the receptor IFNAR1. Nat. Immunol. 14:901-7
104. Schoggins JW,Wilson SJ, Panis M, Murphy MY, Jones CT, et al. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-85
105. Khabar KS, Al-Haj L, Al-Zoghaibi F,Marie M, Dhalla M, et al. 2004. Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J. Mol. Biol. 342:833-46
106. Bolen CR, Ding S, RobekMD, Kleinstein SH. 2014. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59:1262-72
107. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32:513-45
108. da Silva AJ, Brickelmaier M, Majeau GR, Lukashin AV, Peyman J, et al. 2002. Comparison of gene expression patterns induced by treatment of human umbilical vein endothelial cells with IFN-α2b versus IFN-β1a: understanding the functional relationship between distinct type I interferons that act through a common receptor. J. Interferon Cytokine Res. 22:173-88
109. Moraga I, Spangler J, Mendoza JL, Garcia KC. 2014. Multifarious determinants of cytokine receptor signaling specificity. Adv. Immunol. 121:1-39
110. Stemmer WP. 1994. DNA shuffling by random fragmentation and reassembly: in vitro recombination for molecular evolution. PNAS 91:10747-51
111. Stemmer WP. 1994. Rapid evolution of a protein in vitro by DNA shuffling. Nature 370:389-91
112. Chang CC, Chen TT, Cox BW, Dawes GN, Stemmer WP, et al. 1999. Evolution of a cytokine using DNA family shuffling. Nat. Biotechnol. 17:793-97
113. Bekisz J, Baron S,BalinskyC,MorrowA, Zoon KC. 2010. Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3:994-1015
114. Grimley PM, Fang H, Rui H, Petricoin EF 3rd, Ray S, et al. 1998. Prolonged STAT1 activation related to the growth arrest of malignant lymphoma cells by interferon-α. Blood 91:3017-27
115. Silverman RH, Watling D, Balkwill FR, Trowsdale J, Kerr IM. 1982. The ppp(A2'p)nA and protein kinase systems in wild-type and interferon-resistant Daudi cells. Eur. J. Biochem. 126:333-41
116. Pereira AA, Jacobson IM. 2009. New and experimental therapies for HCV. Nat. Rev. Gastroenterol. Hepatol. 6:403-11
117. Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA. 2008. Mutation of the IFNAR-1 receptor binding site of human IFN-α2 generates type I IFN competitive antagonists. Biochemistry 47:12018-27
118. Darnell JE Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-21
119. Ivashkiv LB, Donlin LT. 2014. Regulation of type I interferon responses. Nat. Rev. Immunol. 14:36-49
120. Liao W, Lin JX, LeonardWJ. 2013. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13-25
121. Boyman O, Sprent J. 2012. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12:180-90
122. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, et al. 2008. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293-301
123. Smith FO, Downey SG,Klapper JA, Yang JC, Sherry RM, et al. 2008. Treatment ofmetastaticmelanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14:5610-18
124. Pellegrini M, Mak TW, Ohashi PS. 2010. Fighting cancers from within: augmenting tumor immunity with cytokine therapy. Trends Pharmacol. Sci. 31:356-63
125. Boyman O, Surh CD, Sprent J. 2006. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin. Biol. Ther. 6:1323-31
126. McDermott DF, Atkins MB. 2004. Application of IL-2 and other cytokines in renal cancer. Expert Opin. Biol. Ther. 4:455-68
127. Rosenberg SA, Yang JC,White DE, Steinberg SM. 1998. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228:307-19
128. Rosenberg SA. 2012. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4:127ps8
129. Kim HP, Imbert J, Leonard WJ. 2006. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 17:349-66
130. Taniguchi T, Minami Y. 1993. The IL-2/IL-2 receptor system: a current overview. Cell 73:5-8
131. Liao W, Lin JX, LeonardWJ. 2011. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23:598-604
132. Malek TR, Bayer AL. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4:665-74
133. Wang X, Rickert M, Garcia KC. 2005. Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors. Science 310:1159-63
134. Stauber DJ, Debler EW,Horton PA, Smith KA, Wilson IA. 2006. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. PNAS 103:2788-93
135. Rao BM, Driver I, Lauffenburger DA, Wittrup KD. 2005. High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth. Biochemistry 44:10696-701
136. Liu DV, Maier LM, Hafler DA, Wittrup KD. 2009. Engineered interleukin-2 antagonists for the inhibition of regulatory T cells. J. Immunother. 32:887-94
137. Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, et al. 2013. Human IL-2mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190:6230-38
138. Zurawski SM, Zurawski G. 1992. Receptor antagonist and selective agonist derivatives of mouse interleukin-2. EMBO J. 11:3905-10
139. Margolin K, Atkins MB, Dutcher JP, Ernstoff MS, Smith JW 2nd, et al. 2007. Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin. Cancer Res. 13:3312-19
140. Davey RT, Pertel PE, Benson A, Cassell DJ, Gazzard BG, et al. 2008. Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. J. Interferon Cytokine Res. 28:89-100
141. Matthews L, Chapman S, Ramchandani MS, Lane HC, Davey RT Jr, Sereti I. 2004. BAY 50-4798, a novel, high-affinity receptor-specific recombinant interleukin-2 analog, induces dose-dependent increases inCD25 expression and proliferation among unstimulated, human peripheral blood mononuclear cells in vitro. Clin. Immunol. 113:248-55
142. Krieg C, Letourneau S, Pantaleo G, Boyman O. 2010. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. PNAS 107:11906-11
143. Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, et al. 2013. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur. J. Cancer 49:35-44
144. Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, et al. 2013. T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein. J. Transl. Med. 11:5
145. Hemar A, Subtil A, Lieb M, Morelon E, Hellio R, Dautry-Varsat A. 1995. Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor α, β, and γchains. J. Cell Biol. 129:55-64
146. Gesbert F, Sauvonnet N, Dautry-Varsat A. 2004. Clathrin-independent endocytosis and signalling of interleukin 2 receptors IL-2R endocytosis and signalling. Curr. Top. Microbiol. Immunol. 286:119-48
147. Berndt WG, Chang DZ, Smith KA, Ciardelli TL. 1994. Mutagenic analysis of a receptor contact site on interleukin-2: preparation of an IL-2 analog with increased potency. Biochemistry 33:6571-77
148. Fallon EM, Liparoto SF, Lee KJ, Ciardelli TL, Lauffenburger DA. 2000. Increased endosomal sorting of ligand to recycling enhances potency of an interleukin-2 analog. J. Biol. Chem. 275:6790-97
149. Imler JL, Zurawski G. 1992. Receptor binding and internalization of mouse interleukin-2 derivatives that are partial agonists. J. Biol. Chem. 267:13185-90
150. ChangDZ,WuZ, Ciardelli TL. 1996.Apoint mutation in interleukin-2 that alters ligand internalization. J. Biol. Chem. 271:13349-55
151. Chang DZ, Tasayco ML, Ciardelli TL. 1995. Structural analogs of interleukin-2: a point mutation that facilitates biological response. Mol. Pharmacol. 47:206-11
152. Braisted AC, Oslob JD, Delano WL, Hyde J, McDowell RS, et al. 2003. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125:3714-15
153. Thanos CD,DeLanoWL, Wells JA. 2006. Hot-spot mimicry of a cytokine receptor by a small molecule. PNAS 103:15422-27
154. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. 2006. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 311:1924-27
155. VerdeilG,MarquardtK, SurhCD, Sherman LA. 2008. Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. PNAS 105:16683-88
156. Jin GH, Hirano T, Murakami M. 2008. Combination treatment with IL-2 and anti-IL-2 mAbs reduces tumor metastasis via NK cell activation. Int. Immunol. 20:783-89
157. Tomala J, Kovarova J, Kabesova M, Votavova P, Chmelova H, et al. 2013. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem. Biol. 8:871-76
158. Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6:595-601
159. FehnigerTA, Caligiuri MA. 2001. Interleukin 15: biology and relevance to human disease. Blood 97:14-32
160. Castro I, Yu A, DeeMJ, Malek TR. 2011. The basis of distinctive IL-2-and IL-15-dependent signaling: weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effectormemory cell development. J. Immunol. 187:5170-82
161. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6:1142-51
162. Maloy KJ, Powrie F. 2005. Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat. Immunol. 6:1071-72
163. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. 1998. Potent and selective stimulation of memoryphenotype CD8+ T cells in vivo by IL-15. Immunity 8:591-99
164. Schluns KS, Klonowski KD, Lefrancois L. 2004. Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow-derived cells. Blood 103:988-94
165. Becker TC,Wherry EJ, Boone D,Murali-Krishna K, Antia R, et al. 2002. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J. Exp. Med. 195:1541-48
166. Pettit DK, Bonnert TP, Eisenman J, Srinivasan S, Paxton R, et al. 1997. Structure-function studies of interleukin 15 using site-specificmutagenesis, polyethylene glycol conjugation, and homology modeling. J. Biol. Chem. 272:2312-18
167. Ferrari-Lacraz S, Zheng XX, Kim YS, Li Y, Maslinski W, et al. 2001. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. 167:3478-85
168. Ferrari-Lacraz S, Zanelli E, Neuberg M, Donskoy E, Kim YS, et al. 2004. Targeting IL-15 receptorbearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J. Immunol. 173:5818-26
169. Mortier E, Quemener A, Vusio P, Lorenzen I, Boublik Y, et al. 2006. Soluble interleukin-15 receptor α(IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ: hyperagonist IL-15 IL-15Rαfusion proteins. J. Biol. Chem. 281:1612-19
170. Zhu X, Marcus WD, Xu W, Lee HI, Han K, et al. 2009. Novel human interleukin-15 agonists. J. Immunol. 183:3598-607
171. Han KP, Zhu X, Liu B, Jeng E, Kong L, et al. 2011. IL-15:IL-15 receptor α superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56:804-10
172. Wong HC, Jeng EK, Rhode PR. 2013. The IL-15-based superagonist ALT-803 promotes the antigenindependent conversion of memory CD8 T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2:e26442
173. Junttila IS, Mizukami K, Dickensheets H, Meier-Schellersheim M, Yamane H, et al. 2008. Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity. J. Exp. Med. 205:2595-608
174. Andrews AL, Holloway JW, Holgate ST, Davies DE. 2006. IL-4 receptor αis an important modulator of IL-4 and IL-13 receptor binding: implications for the development of therapeutic targets. J. Immunol. 176:7456-61
175. Sosman JA, Fisher SG, Kefer C, Fisher RI, Ellis TM. 1994. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann. Oncol. 5:447-52
176. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. 2007. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370:1422-31
177. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. 2003. Interleukin-4 and interleukin-13 signaling connections maps. Science 300:1527-28
178. Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, et al. 2002. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J. Immunol. 169:3574-80
179. Shanafelt AB, Forte CP,Kasper JJ, Sanchez-Pescador L, Wetzel M, et al. 1998. An immune cell-selective interleukin 4 agonist. PNAS 95:9454-58
180. Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, et al. 2010. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol. Cell Biol. 88:624-31
181. DauerM, Obermaier B,Herten J,Haerle C, Pohl K, et al. 2003. Mature dendritic cells derived from humanmonocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170:4069-76
182. Wills-Karp M. 2004. Interleukin-13 in asthma pathogenesis. Curr. Allergy Asthma Rep. 4:123-31
183. Zhu J, Yamane H, Paul WE. 2010. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28:445-89
184. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, et al. 1996. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J. Biol. Chem. 271:16921-26
185. Debinski W, Miner R, Leland P, Obiri NI, Puri RK. 1996. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271:22428-33
186. Candolfi M, Kroeger KM, Xiong W, Liu C, Puntel M, et al. 2011. Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation. Anticancer Agents Med. Chem. 11:729-38
187. Debinski W, Obiri NI, Powers SK, Pastan I, Puri RK. 1995. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1:1253-58
188. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, et al. 2007. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 25:837-44
189. Liu H, Jacobs BS, Liu J, Prayson RA, Estes ML, et al. 2000. Interleukin-13 sensitivity and receptor phenotypes of human glial cell lines: non-neoplastic glia and low-grade astrocytoma differ from malignant glioma. Cancer Immunol. Immunother. 49:319-24
190. Liu H, Prayson RA, Estes ML, Drazba JA, Barnett GH, et al. 2000. In vivo expression of the interleukin 4 receptor αby astrocytes in epilepsy cerebral cortex. Cytokine 12:1656-61
191. Debinski W, Gibo DM,Obiri NI, Kealiher A, Puri RK. 1998. Novel anti-brain tumor cytotoxins specific for cancer cells. Nat. Biotechnol. 16:449-53
192. CandolfiM, Xiong W, Yagiz K, Liu C, Muhammad AK, et al. 2010. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. PNAS 107:20021-26
193. Madhankumar AB, Mintz A, DebinskiW. 2004. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Rα2. Neoplasia 6:15-22
194. Skiniotis G, Boulanger MJ, Garcia KC, Walz T. 2005. Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat. Struct. Mol. Biol. 12:545-51
195. Xu Y, Kershaw NJ, Luo CS, Soo P, Pocock MJ, et al. 2010. Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexes. J. Biol. Chem. 285:21214-18
196. Huyton T, Zhang JG, Luo CS, Lou MZ, Hilton DJ, et al. 2007. An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptor. PNAS 104:12737-42
197. Skiniotis G, Lupardus PJ,Martick M, Walz T, Garcia KC. 2008. Structural organization of a full-length gp130/LIF-R cytokine receptor transmembrane complex. Mol. Cell 31:737-48
198. Walter MR. 2004. Structural analysis of IL-10 and type I interferon family members and their complexes with receptor. Adv. Protein Chem. 68:171-223